Appendix S1: Disclosures of Interest

2026 Writing Group Member Relationships with Industry and Other Entities						
Writing Group Member	**Employment**	**Consultant**	**Speakers Bureau**	**Ownership/ Partnership/ Principal**	**Institutional, Organizational or Other Financial Benefit**	**Research**
Bridget R. Durkin, MD, MBE	University of Pennsylvania Health System	None	None	None	None	None
Michael J. Lynch, MD, FACMT	University of Pittsburgh Medical Center	None	None	None	None	None
Jeanmarie Perrone, MD	University of Pennsylvania Perelman School of Medicine	None	None	None	None	None

The above table presents relationships of the Writing Group members during the past 12 months with industry and other entities that were determined to be relevant to this document. These relationships are current as of the completion of this document and may not necessarily reflect relationships at the time of this document's publication. A relationship is considered to be significant if the individual receives compensation that includes cash, shares, and/or anything else of value including direct ownership of shares, stock, stock options or other interest of 5% more of an entity or valued at $10,000 or more (excluding mutual funds), whichever is greater. A relationship is considered to be modest if it is less than significant under the preceding definition. A relationship is considered to be unpaid if the individual does not receive monetary reimbursement. ** Indicates significant relationship. * Indicates modest relationship

2026 Field Reviewers Relationships with Industry and Other Entities						
Field Reviewer	**Employment**	**Consultant**	**Speakers Bureau**	**Ownership/ Partnership/ Principal**	**Institutional, Organizational or Other Financial Benefit**	**Research**
Mohit Chhatpar, DO	Hartford Healthcare	None	None	None	None	None
Joseph D'Orazio, MD, FACPP	Cooper University Hospital	None	None	None	None	None
Philip A. Durney, III, MD	Thomas Jefferson University Hospitals	None	None	None	None	None
Umer Farooq, DO	Christiana Care Hospital	None	None	None	None	None
Dennis Goodstein, PharmD, BCPS	Thomas Jefferson University Hospital	None	None	None	None	None
Ilana W. Hull, MD, MSc	University of Pittsburgh	None	None	None	None	None
Cresta W. Jones, MD, FACOG, FASAM	University of Minnesota Medical School	None	None	None	None	None
Michael R. Lawson, MD	University of Cincinnati Medical Center	None	None	None	None	None
Samuel J. Lee, MD	Esperanza Health Center	None	None	None	None	None
Jessica Moore, MD	Cooper University Health Care	None	None	None	None	None
Jordan Nahas-Vigon, MD	Johns Hopkins Bayview Medical Center	None	None	None	None	None
Kurt D. Palumbo, MS, PA-C	University of Pennsylvania	None	None	None	None	None
Kelly S. Ramsey, MD, MPH, MA, FACP, DFASAM	Kelly S. Ramsey Consulting LLC	Expert Witness**	None	None	None	None
Gregory K. Wanner, DO, FACEP	Christiana Care; Delaware Division of Public Health	None	None	None	None	None
TaReva L. Warrick-Stone, DO	Thomas Jefferson University Hospital	None	None	None	None	Gilead FOCUS*
Scott J. Whetsell, MD, MBA, FAAP, FASAM	Elevance Health	None	None	None	None	None

The above table presents relationships of the field reviewers during the past 12 months with industry and other entities that were determined to be relevant to this document. These relationships are current as of the completion of this document and may not necessarily reflect relationships at the time of this document's publication. A relationship is considered to be significant if the individual receives compensation that includes cash, shares, and/or anything else of value including direct ownership of shares, stock, stock options or other interest of 5% more of an entity or valued at $10,000 or more (excluding mutual funds), whichever is greater. A relationship is considered to be modest if it is less than significant under the preceding definition. A relationship is considered to be unpaid if the individual does not receive monetary reimbursement. ** Indicates significant relationship. * Indicates modest relationship